

# Thierry Jo Molina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4277269/publications.pdf>

Version: 2024-02-01

220  
papers

14,915  
citations

23879

60  
h-index

22488

117  
g-index

237  
all docs

237  
docs citations

237  
times ranked

16384  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenetic landscape of lymphomagenesis in coeliac disease. <i>Gut</i> , 2022, 71, 497-508.	6.1	48
2	The alternative RelB NF- $\kappa$ B subunit is a novel critical player in diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 139, 384-398.	0.6	29
3	Establishing diagnostic criteria for mastocytosis in skin biopsies. <i>Histopathology</i> , 2022, 80, 501-514.	1.6	9
4	Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation. <i>American Journal of Surgical Pathology</i> , 2022, 46, 742-753.	2.1	9
5	Le lymphome de la zone marginale ganglionnaire. <i>Revue Francophone Des Laboratoires</i> , 2022, 2022, 62-69.	0.0	0
6	Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. <i>European Journal of Cancer</i> , 2022, 162, 118-127.	1.3	6
7	Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1356-1364.e2.	2.0	2
8	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2022, 35, 1227-1235.	2.9	5
9	Eosinophilic Pustular Folliculitis of Infancy: A Histologic Assessment of 43 Cases. <i>American Journal of Dermatopathology</i> , 2022, 44, 395-403.	0.3	2
10	Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	7
11	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. <i>Blood Advances</i> , 2022, 6, 6169-6179.	2.5	5
12	Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8585-8585.	0.8	1
13	MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. <i>Modern Pathology</i> , 2021, 34, 647-659.	2.9	16
14	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	0.6	48
15	Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 803-818.e11.	2.0	98
16	Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. <i>European Journal of Cancer</i> , 2021, 143, 158-167.	1.3	10
17	Intraperitoneal bleeding as the initial presentation of Randall-type monoclonal immunoglobulin deposition disease with hepatic involvement. <i>Leukemia and Lymphoma</i> , 2021, 62, 1263-1266.	0.6	0
18	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021, 137, 1765-1776.	0.6	60

#	ARTICLE	IF	CITATIONS
19	Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer. <i>Transplant Infectious Disease</i> , 2021, 23, e13552.	0.7	5
20	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
21	Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosisâ€”a RYTHMIC study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 741-746.	1.4	9
22	Dysregulation of the NRG1/ERBB pathway causes a developmental disorder with gastrointestinal dysmotility in humans. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	24
23	c-Rel Is the Pivotal NF-Î²B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. <i>Frontiers in Oncology</i> , 2021, 11, 638897.	1.3	7
24	Central Nervous System Metastases in Thymic Epithelial Tumors: A Brief Report of Real-World Insight FromÂRYTHMIC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2144-2149.	0.5	5
25	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. <i>Blood</i> , 2021, 138, 3495-3495.	0.6	0
26	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2021, 12, 755623.	2.2	5
27	Soft tissue angiomatosis: another PIK3CA â€related disorder. <i>Histopathology</i> , 2020, 76, 540-549.	1.6	12
28	Pityriasis Lichenoides: A Large Histopathological Case Series With a Focus on Adnexotropism. <i>American Journal of Dermatopathology</i> , 2020, 42, 1-10.	0.3	10
29	Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by <i>TRPV3</i> Mutations. <i>JAMA Dermatology</i> , 2020, 156, 191.	2.0	37
30	Bone Marrow Transplantation in Congenital Erythropoietic Porphyria: Sustained Efficacy but Unexpected Liver Dysfunction. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 704-711.	2.0	10
31	Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	37
32	Mutations in <i>COPA</i> lead to abnormal trafficking of STING to the Golgi and interferon signaling. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	130
33	Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. <i>Haematologica</i> , 2020, 105, e461-464.	1.7	7
34	Gene expression profiling of gray zone lymphoma. <i>Blood Advances</i> , 2020, 4, 2523-2535.	2.5	32
35	STING Gain-of-Function Disrupts Lymph Node Organogenesis and Innate Lymphoid Cell Development in Mice. <i>Cell Reports</i> , 2020, 31, 107771.	2.9	18
36	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. <i>Clinical Cancer Research</i> , 2020, 26, 3145-3153.	3.2	48

#	ARTICLE	IF	CITATIONS
37	Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. <i>British Journal of Haematology</i> , 2020, 189, 244-256.	1.2	21
38	Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. <i>Leukemia and Lymphoma</i> , 2020, 61, 887-895.	0.6	3
39	A toxic palmitoylation of Cdc42 enhances NF- $\kappa$ B signaling and drives a severe autoinflammatory syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1201-1204.e8.	1.5	33
40	Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 59.	2.8	22
41	Chronic Disseminated Aspergillosis, a Novel Fungal Immune Reconstitution Inflammatory Syndrome. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa175.	0.4	2
42	Solid pseudopapillary neoplasms of the pancreas do not express major pancreatic markers in pediatric patients. <i>Human Pathology</i> , 2019, 83, 29-35.	1.1	11
43	Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019, 37, 3359-3368.	0.8	161
44	Diagnosis and Classification. , 2019, , 23-29.		0
45	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019, 29, 1243-1257.e10.	7.2	56
46	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 341-351.	2.1	61
47	OP0107...HETEROZYGOUS MUTATIONS IN COPA ARE ASSOCIATED WITH ENHANCED TYPE I INTERFERON SIGNALLING. , 2019, , .		0
48	Chronic Intestinal Pseudo-Obstruction and Lymphoproliferative Syndrome as a Novel Phenotype Associated With Tetratricopeptide Repeat Domain 7A Deficiency. <i>Frontiers in Immunology</i> , 2019, 10, 2592.	2.2	7
49	Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation. <i>American Journal of Dermatopathology</i> , 2019, 41, 29-36.	0.3	12
50	Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. <i>Biomarker Research</i> , 2019, 7, 28.	2.8	22
51	Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles. <i>EBioMedicine</i> , 2019, 48, 58-69.	2.7	29
52	NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. <i>Gut</i> , 2019, 68, 1396-1405.	6.1	47
53	A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 111-122.	1.2	12
54	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	1.3	6

#	ARTICLE	IF	CITATIONS
55	Loss of ARHGEF1 causes a human primary antibody deficiency. <i>Journal of Clinical Investigation</i> , 2019, 129, 1047-1060.	3.9	32
56	Mutational Landscape of Grey Zone Lymphoma. <i>Blood</i> , 2019, 134, 21-21.	0.6	3
57	Thymic epithelial tumors diagnosis and management: the importance of an international multidisciplinary approach. <i>Mediastinum</i> , 2019, 3, 28-28.	0.6	0
58	Authors'™ Reply. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 266.	1.2	0
59	Necrotizing Infundibular Crystalline Folliculitis: An Unusual Clinical Presentation and Demonstration of the Presence of Calcium Palmitate. <i>American Journal of Dermatopathology</i> , 2018, 40, e9-e11.	0.3	4
60	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
61	Through the Glass Ceiling. <i>Journal of Clinical Oncology</i> , 2018, 36, 923-923.	0.8	0
62	Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1762-1770.	0.5	60
63	Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. <i>Lancet Haematology</i> , 2018, 5, e403-e410.	2.2	21
64	Optimizing initial therapy in DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 199-208.	0.7	15
65	FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
66	Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. <i>Haematologica</i> , 2017, 102, 150-159.	1.7	61
67	Management of aggressive lymphoma in very elderly patients. <i>Hematological Oncology</i> , 2017, 35, 49-53.	0.8	10
68	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	0.6	21
69	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2232-2244.	3.2	82
70	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 892-904.	1.2	39
71	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
72	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. <i>Haematologica</i> , 2017, 102, e404-e406.	1.7	16

#	ARTICLE	IF	CITATIONS
73	Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 221-230.	1.5	10
74	Response to 5-azacytidine in a patient with <i>TET2</i> -mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 864-868.	0.8	33
75	Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies: Table 1.. <i>Clinical Infectious Diseases</i> , 2017, 64, 83-86.	2.9	66
76	Antithrombin is not protective against renal ischaemia-reperfusion injury. <i>Thrombosis and Haemostasis</i> , 2017, 117, 422-425.	1.8	0
77	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , 2017, 35, 2008-2017.	0.8	155
78	Skin Biopsy in Netherton Syndrome. <i>American Journal of Dermatopathology</i> , 2016, 38, 83-91.	0.3	26
79	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 251-267.	1.5	75
80	Recurrent mutations of the exportin 1 gene ( <i>XPO1</i> ) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	2.0	79
81	Optimizing therapy for nodal marginal zone lymphoma. <i>Blood</i> , 2016, 127, 2064-2071.	0.6	59
82	Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase $\gamma$ syndrome 2: A cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 210-218.e9.	1.5	215
83	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. <i>Clinical Cancer Research</i> , 2016, 22, 2919-2928.	3.2	181
84	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	1.4	52
85	Pathological central review of 290 thymic epithelial tumors (TET): The national network RYTHMIC experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8568-8568.	0.8	4
86	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	1.1	19
87	Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7547-7547.	0.8	0
88	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and Non-L265P Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. <i>Blood</i> , 2016, 128, 4097-4097.	0.6	0
89	Integrated Analysis of IGHV Gene Status, Cell-of-Origin Signature and Genomic Features in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4118-4118.	0.6	0
90	Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. <i>Haematologica</i> , 2015, 100, e361-e364.	1.7	98

#	ARTICLE	IF	CITATIONS
91	MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. <i>Blood</i> , 2015, 126, 2466-2474.	0.6	212
92	Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. <i>Pathology Research and Practice</i> , 2015, 211, 996-1002.	1.0	13
93	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lymphoC study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	2.0	84
94	Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 273-283.	1.2	50
95	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	0.8	24
96	Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study. <i>Blood</i> , 2015, 126, 129-129.	0.6	2
97	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. <i>Blood</i> , 2015, 126, 1464-1464.	0.6	2
98	Langerhans cell histiocytosis in children: Correlation of <i>BRAF</i> status with clinical characteristic.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10003-10003.	0.8	0
99	Abstract 4810: Exome sequencing of refractory diffuse large B-cell lymphomas highlights candidate genes for targeted resequencing. , 2015, , .		0
100	Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study. <i>Blood</i> , 2015, 126, 1472-1472.	0.6	0
101	Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. <i>Journal of Clinical Investigation</i> , 2014, 124, 5516-5520.	3.9	435
102	Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	0.8	79
103	ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting. <i>Journal of Thoracic Oncology</i> , 2014, 9, 596-611.	0.5	247
104	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
105	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	0.8	304
106	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	1.7	52
107	Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. <i>Blood</i> , 2014, 124, 1597-1609.	0.6	48
108	Final results of a randomized phase II GELA/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8503-8503.	0.8	2

#	ARTICLE	IF	CITATIONS
109	National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France.. Journal of Clinical Oncology, 2014, 32, 7605-7605.	0.8	0
110	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 525-533.	5.1	257
111	Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2013, 54, 1898-1907.	0.6	36
112	Autoimmune Hemolytic Anemia and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Rare Association. Case Reports in Hematology, 2013, 2013, 1-5.	0.3	3
113	Reproducibility of Immunohistochemical Scoring for Epidermal Growth Factor Receptor Expression in Non-Small Cell Lung Cancer: Round Robin Test. Archives of Pathology and Laboratory Medicine, 2013, 137, 1255-1261.	1.2	25
114	Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia, 2013, 27, 252-255.	3.3	42
115	Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple Myeloma. PLoS ONE, 2013, 8, e59127.	1.1	29
116	Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study. Blood, 2013, 122, 248-248.	0.6	6
117	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	0.6	1
118	First Lymphoma Study Association workshops Deauville (France), 10th-12th October 2013 - Apart 1. Hematologie, 2013, 19, 396-407.	0.0	0
119	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Frontiers in Immunology, 2012, 3, 98.	2.2	14
120	Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. Annals of Oncology, 2012, 23, 3143-3151.	0.6	46
121	Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non-Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim. British Journal of Haematology, 2012, 156, 145-147.	1.2	7
122	Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology, 2012, 23, 30-38.	0.4	117
123	Expression of MYC, IgM, As Well As Non-Germinal Centre B-Cell Like Immunophenotype and Positive Immunofish Index Predict a Worse Progression Free Survival and Overall Survival in a Series of 670 De Novo Diffuse Large B-Cell Lymphomas Included in Clinical Trials: A GELA Study of the 2003 Program. Blood, 2012, 120, 1539-1539.	0.6	1
124	Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe. Blood, 2012, 120, 1607-1607.	0.6	3
125	Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2B Tumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program. Blood, 2012, 120, 415-415.	0.6	6
126	Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03-6B GELA Study.. Blood, 2012, 120, 2723-2723.	0.6	1



#	ARTICLE	IF	CITATIONS
127	Toxicity of Carbon Dioxide: A Review. <i>Chemical Research in Toxicology</i> , 2011, 24, 2061-2070.	1.7	64
128	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNHO3-2B): an open-label randomised phase 3 trial. <i>Lancet, The</i> , 2011, 378, 1858-1867.	6.3	311
129	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168
130	Nodal intralymphatic papillary endothelial tumour with Dabska-like features: report of a case in two mesenteric lymph nodes. <i>Histopathology</i> , 2011, 59, 1027-1029.	1.6	5
131	Pathologie moléculaire des lymphomes diffus à grandes cellules B : intérêt diagnostique et pronostique pour l'histopathologiste. <i>Revue Francophone Des Laboratoires</i> , 2011, 2011, 57-64.	0.0	1
132	Preoperative Circulating Tumor Cell Detection Using the Isolation by Size of Epithelial Tumor Cell Method for Patients with Lung Cancer Is a New Prognostic Biomarker. <i>Clinical Cancer Research</i> , 2011, 17, 827-835.	3.2	281
133	Lymphoplasmacytic Lymphoma and Other Non-Marginal Zone Lymphomas With Plasmacytic Differentiation. <i>American Journal of Clinical Pathology</i> , 2011, 136, 195-210.	0.4	72
134	Cytopathologic Detection of Circulating Tumor Cells Using the Isolation by Size of Epithelial Tumor Cell Method. <i>American Journal of Clinical Pathology</i> , 2011, 135, 146-156.	0.4	122
135	Marginal Zone Lymphomas With Plasmacytic Differentiation and Related Disorders. <i>American Journal of Clinical Pathology</i> , 2011, 136, 211-225.	0.4	76
136	Dacarbazine Promotes Stromal Remodeling and Lymphocyte Infiltration in Cutaneous Melanoma Lesions. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1896-1905.	0.3	33
137	Phase I Study of Escalating Doses of Lenalidomide Combined with R-CHOP (R2-CHOP) for Front-Line Treatment of B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 1632-1632.	0.6	13
138	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNHO3-2B. <i>Blood</i> , 2011, 118, 2632-2632.	0.6	5
139	Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNHO3-6B study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 9048-9048.	0.8	18
140	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. <i>Blood</i> , 2010, 116, 1092-1104.	0.6	122
141	Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNHO3-2 protocol. <i>Leukemia and Lymphoma</i> , 2010, 51, 1668-1677.	0.6	2
142	Carbon dioxide is largely responsible for the acute inflammatory effects of tobacco smoke. <i>Inhalation Toxicology</i> , 2010, 22, 543-551.	0.8	15
143	A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNHO3-2B. <i>Blood</i> , 2010, 116, 109-109.	0.6	14
144	A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2010, 28, TPS297-TPS297.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Physiopathologie des lymphomes diffus à grandes cellules B. <i>Hematologie</i> , 2009, 15, 214-222.	0.0	0
146	Immuno-fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579.	0.8	113
147	CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. <i>Journal of Experimental Medicine</i> , 2009, 206, 595-606.	4.2	364
148	The detection of CD14 and CD16 in paraffin-embedded bone marrow biopsies is useful for the diagnosis of chronic myelomonocytic leukemia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 411-419.	1.4	22
149	Composite mantle cell and follicular lymphoma. A case report. <i>Human Pathology</i> , 2009, 40, 259-263.	1.1	19
150	Nodal follicular helper T-cell lymphoma may present with different patterns. A case report. <i>Human Pathology</i> , 2009, 40, 264-269.	1.1	15
151	Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 410-418.	0.6	4
152	Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. <i>Blood</i> , 2009, 113, 2765-3775.	0.6	224
153	Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon- $\gamma$ expression. <i>Blood</i> , 2009, 113, 6112-6119.	0.6	66
154	R-CHOP14 Compared to R-CHOP21 in Elderly Patients with Diffuse Large B-Cell Lymphoma: Results of the Interim Analysis of the LNH03-6B GELA Study. <i>Blood</i> , 2009, 114, 406-406.	0.6	23
155	Le rôle de l'histopathologie dans le diagnostic des syndromes lymphoprolifératifs B chroniques. <i>Revue Francophone Des Laboratoires</i> , 2008, 2008, 73-79.	0.0	1
156	The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. <i>Leukemia</i> , 2008, 22, 1917-1924.	3.3	95
157	T Cell Receptor Genotyping and HOXA/TLX1 Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome. <i>Clinical Cancer Research</i> , 2008, 14, 692-700.	3.2	43
158	Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. <i>Blood</i> , 2008, 112, 2520-2528.	0.6	141
159	Herpes-Virus Infection in Patients with Langerhans Cell Histiocytosis: A Case-Controlled Sero-Epidemiological Study, and In Situ Analysis. <i>PLoS ONE</i> , 2008, 3, e3262.	1.1	48
160	Multiple Secondary Genetic Events Inducing Histologic Progression (HP) of Non-MALT Marginal Zone Lymphoma (MZL): An Integrated Genomic Analysis of Genome-Wide Copy-Number-Changes (CNC) and Transcriptomic Data. <i>Blood</i> , 2008, 112, 1198-1198.	0.6	0
161	Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study. <i>Blood</i> , 2008, 112, 803-803.	0.6	0
162	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 787-792.	0.8	239

#	ARTICLE	IF	CITATIONS
163	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applicationsâ€”A Study From the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2007, 25, 805-812.	0.8	271
164	Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. <i>Journal of Leukocyte Biology</i> , 2007, 82, 567-575.	1.5	62
165	The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. <i>Blood</i> , 2007, 109, 4952-4963.	0.6	533
166	Improved reliability of lymphoma diagnostics via PCR-based clonality testing: â€” Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007, 21, 201-206.	3.3	279
167	Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. <i>Leukemia</i> , 2007, 21, 207-214.	3.3	292
168	Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. <i>Leukemia</i> , 2007, 21, 215-221.	3.3	222
169	Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2007, 21, 222-229.	3.3	143
170	Primary mediastinal anaplastic alk-1-positive large-cell lymphoma of T/NK-cell type expressing CD20. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 355-358.	1.4	18
171	Germinal Center Phenotype Determined by Immunohistochemistry on Tissue Microarray Does Not Correlate with Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy in the Randomized Trial LNH98-5. A GELA Study.. <i>Blood</i> , 2007, 110, 51-51.	0.6	4
172	Distinct Expression Patterns of microRNAs in Activated B Cell (ABC) and Germinal Center B (GC) Subtypes of Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 562-562.	0.6	0
173	CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169â€™ monocyte-derived cells in diffuse large B-cell lymphomas. <i>Human Pathology</i> , 2006, 37, 68-77.	1.1	45
174	Lymphomes: De la Biologie Ã la Clinique. <i>Revue Francophone Des Laboratoires</i> , 2006, 2006, 17-19.	0.0	0
175	Florid marginal zone differentiation in follicular lymphoma mimicking marginal zone lymphoma of MALT type in the lung. <i>Histopathology</i> , 2006, 49, 426-429.	1.6	11
176	Marginal zone lymphoma of both spleen and kidney displaying transformation into large B-cell lymphoma. <i>International Urology and Nephrology</i> , 2006, 38, 431-437.	0.6	2
177	A steroid-refractory ulcerative colitis revealing Epsteinâ€™Barr virus/cytomegalovirus-positive colonic lymphoma. <i>International Journal of Colorectal Disease</i> , 2006, 21, 288-290.	1.0	10
178	Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication. <i>Gut</i> , 2006, 55, 137-138.	6.1	61
179	The Gene Expression Profile of Nodal T-Cell Lymphomas Identifies a Molecular Link between Angioimmunoblastic T-Cell Lymphoma (AITL) and Follicular Helper T Cells (TFH), and between CD30+ Peripheral T-Cell Lymphoma and ALK-Negative Anaplastic Large Cell Lymphoma (ALCL).. <i>Blood</i> , 2006, 108, 289-289.	0.6	3
180	Concomitant Epstein-Barr Virusâ€™Negative Large B-Cell Lymphoma (Richter Syndrome) and Epstein-Barr Virusâ€™Positive B-Cell Lymphoproliferation After Treatment With Fludarabine and Cyclophosphamide in a Patient With B-Cell Chronic Lymphocytic Leukemia. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1227-1230.	1.2	5

#	ARTICLE	IF	CITATIONS
181	Perioperative analysis of biopsies issued from mediastinoscopy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2005, 19, 1456-1459.	1.3	3
182	Consecutive Conjunctival Melanoma and Extranodal Marginal Zone B-Cell Lymphoma of MALT Type in an Adult Patient. <i>JAMA Ophthalmology</i> , 2005, 123, 397.	2.6	0
183	ACVBP versus CHOP plus Radiotherapy for Localized Aggressive Lymphoma. <i>New England Journal of Medicine</i> , 2005, 352, 1197-1205.	13.9	311
184	Conditional hepatocarcinogenesis in mice expressing SV 40 early sequences. <i>Cancer Letters</i> , 2005, 229, 107-114.	3.2	16
185	Primary Splenic and Nodal Marginal Zone Lymphoma: <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2005, 45, 1-14.	0.3	5
186	CD10 expression in diffuse large B-cell lymphomas does not influence survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 545-551.	1.4	32
187	Fc $\gamma$ RIIB is differentially expressed during B cell maturation and in B-cell lymphomas. <i>British Journal of Haematology</i> , 2004, 124, 55-62.	1.2	25
188	Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. <i>British Journal of Haematology</i> , 2003, 122, 404-412.	1.2	57
189	Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2003, 102, 4284-4289.	0.6	306
190	Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000). <i>British Journal of Cancer</i> , 2003, 89, S35-S49.	2.9	24
191	An unusual cause of hiccup: costal exostosis. Treatment by video-assisted thoracic surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2003, 23, 1056-1058.	0.6	26
192	Myeloid Sarcoma: Clinical and Morphologic Criteria Useful for Diagnosis. <i>International Journal of Surgical Pathology</i> , 2003, 11, 271-282.	0.4	113
193	Visceral Larva Migrans Mimicking Lymphoma. <i>Chest</i> , 2003, 123, 1296-1297.	0.4	25
194	Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2472-2479.	0.8	194
195	T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. <i>Gastroenterology</i> , 2002, 122, 1286-1294.	0.6	397
196	Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. <i>British Journal of Haematology</i> , 2002, 118, 210-217.	1.2	25
197	Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. <i>Lancet, The</i> , 2001, 357, 39-40.	6.3	435
198	Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. <i>Gut</i> , 2001, 48, 297-303.	6.1	251

#	ARTICLE	IF	CITATIONS
199	Splenic Marginal Zone Lymphoma With or Without Plasmacytic Differentiation. American Journal of Surgical Pathology, 2000, 24, 1581-1592.	2.1	72
200	Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 591-598.	1.4	26
201	Quality control and sensitivity of polymerase chain reaction techniques for the assessment of immunoglobulin heavy chain gene rearrangements from fixed- and paraffin-embedded samples. Annals of Diagnostic Pathology, 2000, 4, 71-76.	0.6	19
202	Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood, 2000, 96, 1921-5.	0.6	268
203	Diffuse mucosal damage in the large intestine associated with Irinotecan (CPT-11). Digestive Diseases and Sciences, 1998, 43, 2649-2651.	1.1	9
204	Retinal dysplasia in mice lacking p56lck. Oncogene, 1998, 16, 2351-2356.	2.6	31
205	The amino-terminal region of SV40 large T antigen is sufficient to induce hepatic tumours in mice. Oncogene, 1998, 17, 1253-1259.	2.6	16
206	Respiratory Distress due to Tracheal Aspergillosis in a Severely Immunocompromised Patient. Acta Haematologica, 1998, 100, 85-87.	0.7	11
207	Multiple lymphomatous polyposis of the gastrointestinal tract: Prospective clinicopathologic study of 31 cases. Gastroenterology, 1997, 112, 7-16.	0.6	140
208	The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene, 1997, 14, 395-404.	2.6	278
209	Analysis of a Murine Thymic Carcinogenesis Model Induced by the Expression of Large T of SV40. , 1997, , 155-156.		0
210	Spi-1/PU.1 Transgenic Mice Develop Multistep Erythroleukemias. Molecular and Cellular Biology, 1996, 16, 2453-2463.	1.1	196
211	ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Current Biology, 1996, 6, 1192-1195.	1.8	91
212	Detection of bcl-2 rearrangement in HIV-1 related follicular lymphoid hyperplasia. British Journal of Haematology, 1996, 94, 705-708.	1.2	9
213	Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nature Medicine, 1996, 2, 80-86.	15.2	380
214	The Lck Tyrosine Kinase Is Expressed in Brain Neurons. Journal of Neurochemistry, 1996, 67, 1360-1364.	2.1	47
215	Tissue-specific and Hormonal Regulation of Calbindin-D9K Fusion Genes in Transgenic Mice. Journal of Biological Chemistry, 1996, 271, 16820-16826.	1.6	33
216	T lymphocyte development in p56lck deficient mice: allelic exclusion of the TcR $\beta$ locus is incomplete but thymocyte development is not restored by TcR $\beta$ or TcR $\beta$ transgenes. European Journal of Immunology, 1995, 25, 1312-1318.	1.6	51

#	ARTICLE	IF	CITATIONS
217	Allo-skin graft rejection, tumor rejection and natural killer activity in mice lacking p56lck. <i>European Journal of Immunology</i> , 1995, 25, 3155-3159.	1.6	44
218	Profound block in thymocyte development in mice lacking p56lck. <i>Nature</i> , 1992, 357, 161-164.	13.7	959
219	Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. <i>Journal of Hepatology</i> , 1991, 13, 227-239.	1.8	80
220	Paraganglioma of the urinary bladder: Immunohistochemical, ultrastructural, and DNA flow cytometric studies. <i>Human Pathology</i> , 1991, 22, 1162-1169.	1.1	64